The U.S. Food & Drug Administration (FDA) has approved a treatment for people with amyotrophic lateral sclerosis (ALS) caused by a mutation in the superoxide dismutase 1 (SOD1) gene. The FDA described Qalsody (also known as tofersen) as “an antisense oligonucleotide that targets SOD1 mRNA to reduce the synthesis of SOD1 protein.” Qalsody is administered…